GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) -October 23, 2023 at 08:28 am EDT
GALLANT-1: GB1211 Galectin-3 inhibitor plus atezolizumab for first line treatment in patients ...
Source: marketscreener.com